The Science Behind Liver Health Supplements

Therapeutic dose: 420–600 mg/day silymarin (standardized to 70–80% silybin)

See ranked Milk Thistle (Silymarin) products→

• Cochrane systematic review (2007, 18 RCTs, 1,088 patients) assessed milk thistle for alcoholic and hepatitis B/C liver disease. Found no significant effect on mortality or liver histology, but noted serious methodological limitations in available trials and called for higher-quality research.PubMed ↗
• SyNCH trial (2012, 154 patients with chronic hepatitis C non-responders) found intravenous silibinin significantly reduced HCV RNA, demonstrating potent antiviral activity — though this used IV administration, not oral.PubMed ↗
• 2016 meta-analysis of 8 RCTs found silymarin significantly reduced ALT and AST levels in NAFLD patients, suggesting hepatoprotective benefit in fatty liver disease.PubMed ↗
• Widely used in integrative hepatology despite mixed trial data. Mechanism involves free radical scavenging, membrane stabilization, and anti-fibrotic activity via stellate cell inhibition. Oral bioavailability is poor (20–50%); phosphatidylcholine-complexed forms (Siliphos) improve absorption significantly.
• Honest limitation: the Cochrane review conclusion was equivocal — milk thistle has not been shown to reduce mortality or improve hard clinical endpoints in liver disease. Most positive trials are for surrogate markers (liver enzymes), not patient-centered outcomes.

Therapeutic dose: 600–1,800 mg/day (oral supplementation); 150 mg/kg IV loading dose (emergency)

See ranked NAC (N-Acetylcysteine) products→

• NAC is the standard of care for acetaminophen (paracetamol) overdose worldwide. The Prescott protocol (1979) established IV NAC as life-saving treatment, reducing hepatotoxicity mortality from ~5% to <0.5% when administered within 8 hours.PubMed ↗
• 2009 RCT (173 patients with non-acetaminophen acute liver failure) found IV NAC improved transplant-free survival in early-stage hepatic encephalopathy (52% vs 30%), establishing benefit beyond acetaminophen toxicity.PubMed ↗
• 2021 meta-analysis of 5 RCTs found NAC supplementation significantly reduced ALT levels in NAFLD patients. Effects were modest but consistent across trials.PubMed ↗
• Mechanism: NAC is a precursor to glutathione, the liver's primary endogenous antioxidant. Replenishes hepatic glutathione stores depleted by oxidative stress, alcohol, and drug metabolism.
• Important nuance: emergency IV NAC dosing is vastly different from oral supplementation. Oral bioavailability is only 6–10%. Supplement doses (600–1,800 mg/day) support glutathione synthesis but should not be conflated with the acute toxicity protocol.

Therapeutic dose: 550 mg/day (men), 425 mg/day (women) — Adequate Intake

See ranked Choline products→

• Choline is the only nutrient for which inadequate intake directly causes liver disease. A landmark depletion study (2007, 57 adults) showed 73% of men and 44% of postmenopausal women developed fatty liver or muscle damage on low-choline diets.PubMed ↗
• Cross-sectional analysis of NHANES data (2003–2014) found higher choline intake was associated with lower risk of NAFLD, particularly in women. ~90% of Americans do not meet the Adequate Intake for choline.PubMed ↗
• Choline is required for VLDL synthesis — the mechanism by which the liver exports triglycerides. Without adequate choline, fat accumulates in hepatocytes, progressing to steatosis.
• FDA recognized choline as an essential nutrient in 1998. It remains under-consumed in Western diets. Eggs, liver, and soybeans are primary dietary sources.

Therapeutic dose: 500–1,500 mg/day (standard extract) or 80–200 mg (enhanced bioavailability forms)

See ranked Curcumin (Turmeric Extract) products→

• 2019 meta-analysis of 6 RCTs found curcumin supplementation significantly reduced ALT, AST, and serum lipids in NAFLD patients.PubMed ↗
• 2016 RCT (80 patients with NAFLD) showed 1,000 mg/day curcumin for 8 weeks significantly reduced hepatic fat content on ultrasound and improved liver enzymes vs placebo.PubMed ↗
• Anti-inflammatory mechanism via NF-kB and TNF-alpha suppression is well characterized. Also activates Nrf2 pathway, upregulating endogenous antioxidant defenses in hepatocytes.
• Standard curcumin has 1–2% oral bioavailability. Enhanced forms (Meriva, Theracurmin, Longvida) are essential for liver-relevant tissue concentrations. Rare cases of liver injury have been reported with high-dose curcumin — paradoxical but documented in case reports.

Therapeutic dose: 300–600 mg/day

See ranked Alpha-Lipoic Acid (ALA) products→

• 2019 meta-analysis of 5 RCTs found ALA supplementation significantly reduced ALT, AST, and triglyceride levels in NAFLD patients.PubMed ↗
• 2012 RCT (45 NAFLD patients) showed 1,200 mg/day ALA for 6 months significantly improved liver enzymes and insulin resistance compared to placebo.PubMed ↗
• Unique dual solubility — both water- and fat-soluble — allows it to regenerate other antioxidants (vitamin C, vitamin E, glutathione). R-lipoic acid is the biologically active enantiomer; racemic mixtures are more common in supplements.

Therapeutic dose: 600–2,400 mg/day (leaf extract)

See ranked Artichoke (Cynara scolymus) products→

• 2018 meta-analysis of 9 RCTs found artichoke leaf extract significantly reduced total cholesterol, LDL, and triglycerides. Several trials also showed reduced ALT levels.PubMed ↗
• 2018 RCT (90 patients with NAFLD) showed 600 mg/day artichoke extract for 2 months significantly reduced ALT, AST, and total bilirubin levels vs placebo.PubMed ↗
• Active compounds (cynarin, luteolin, chlorogenic acid) stimulate bile production (choleretic effect) and protect hepatocytes from oxidative damage. Traditional use in European phytotherapy is well-documented.

Therapeutic dose: 900–1,500 mg/day (divided doses)

• 2013 meta-analysis of 27 RCTs found berberine significantly improved blood glucose, lipids, and insulin resistance — metabolic parameters relevant to NAFLD pathogenesis.PubMed ↗
• 2020 RCT (100 NAFLD patients) found berberine 500 mg TID for 16 weeks improved hepatic fat content and liver enzymes, but the trial was open-label and unblinded.PubMed ↗
• Honest limitation: most berberine-liver studies are from Chinese databases with methodological concerns. Liver-specific evidence is indirect — benefits likely mediated through metabolic improvement rather than direct hepatoprotection. Also, berberine inhibits CYP enzymes, raising drug interaction concerns.

Therapeutic dose: Not established from clinical data (traditional: 3–10 g dried root/day)

See ranked Dandelion (Taraxacum officinale) products→

• In vitro studies show dandelion root extract reduces lipid accumulation in hepatocytes and has antioxidant properties. Animal models show hepatoprotective effects against CCl4-induced liver damage.
• No human RCTs for liver-specific outcomes exist as of 2025. All liver claims are extrapolated from cell culture, animal models, and traditional European/Chinese herbal medicine use.
• Widely marketed as a liver detox ingredient despite complete absence of clinical evidence. This is a clear example of traditional use not translating to demonstrated efficacy.

Therapeutic dose: 250–1,000 mcg/day (when deficient)

See ranked Vitamin B12 (Cobalamin) products→

• B12 is a cofactor in methionine synthase, part of one-carbon metabolism critical for methylation reactions in the liver. Deficiency impairs homocysteine clearance and can elevate hepatic oxidative stress.
• Observational studies link low serum B12 to NAFLD severity, but this may reflect liver disease impairing B12 storage rather than deficiency causing liver damage. Causality is unclear.
• No RCTs have demonstrated that B12 supplementation improves liver outcomes in non-deficient individuals. Supplementation is warranted only when deficiency is documented.

Therapeutic dose: 1.3–10 mg/day

See ranked Vitamin B6 (Pyridoxine) products→

• B6 is required for transamination reactions and amino acid metabolism in the liver. Deficiency is common in alcoholic liver disease but is a consequence, not a cause, of hepatic dysfunction.
• No RCTs support B6 supplementation for liver protection or NAFLD improvement in non-deficient adults. Included in many liver support formulas based on methylation pathway theory rather than clinical evidence.

Therapeutic dose: 400–800 mcg DFE/day

See ranked Folate (Vitamin B9) products→

• Folate is essential for one-carbon metabolism and DNA methylation. Animal studies show folate deficiency exacerbates hepatic steatosis and fibrosis. Methyl-donor depletion diets (low choline + low folate) reliably induce NAFLD in rodents.
• Observational data from NHANES suggests inverse association between folate intake and NAFLD prevalence, but confounding is significant (folate tracks with overall diet quality).
• No RCTs demonstrate that folate supplementation reverses or prevents liver disease in humans with adequate dietary intake. Supplementation is warranted for deficiency correction, not as a liver-specific intervention.